1. Rivaroxaban Compared with Standard Anticoagulants for the Treatment of Acute Venous Thromboembolism in Children: a Randomised, Controlled, Phase 3 Trial
- Author
-
Male, C., Lensing, A. W. A., Palumbo, J. S., Kumar, R., Nurmeev, I., Hege, K., Bonnet, D., Connor, P., Hooimeijer, H. L., Torres, M., Chan, A. K. C., Kenet, G., Holzhauer, S., Santamaría, A., Amedro, P., Chalmers, E., Simioni, P., Bhat, R. V., Yee, D. L., Lvova, O., Beyer-Westendorf, J., Biss, T. T., Martinelli, I., Saracco, P., Peters, M., Kállay, K., Gauger, C. A., Massicotte, M. P., Young, G., Pap, A. F., Majumder, M., Smith, W. T., Heubach, J. F., Berkowitz, S. D., Thelen, K., Kubitza, D., Crowther, M., Prins, M. H., Monagle, P., Molinari, A. C., Nowak, Göttl, U., Chain, J., Robertson, J., Thom, K., Streif, W., Schwarz, R., Schmitt, K., Grangl, G., Van Damme, A., Maes, P., Labarque, V., Petrilli, A., Loggeto, S., Azeka, E., Brandao, L., Le, D., Sabapathy, C., Giordano, P., Wu, R., Ding, J., Huang, W., Mao, J., Lähteenmäki, P., Decramer, S., Bernig, T., Chada, M., Chan, G., Kally, K., Nolan, B., Revel-Vilk, S., Tamary, H., Levin, C., Tormene, D., Abbattista, M., Artoni, A., Ikeyama, T., Inuzuka, R., Yasukochi, S., Morales Soto, M., Solis Labastida, K. A., Suijker, M. H., Bartels, M., Tamminga, R. Y., Van Ommen, C. H., Te Loo, D. M., Anjos, R., Zubarovskaya, L., Popova, N., Samochatova, E., Belogurova, M., Svirin, P., Shutova, T., Lebedev, V., Barbarash, O., Koh, P. L., Mei, J. C., Podracka, L., Berrueco, R., Fernandez, M. F., Frisk, T., Grunt, S., Rischewski, J., Albisetti-Pedroni, M., Antmen, A., Tokgoz, H., Karakas, Z., Motwani, J., Williams, M., Grainger, J., Payne, J., Richards, M., Baird, S., Bhatnagar, N., Aramburo, A., Crary, S., Wynn, T., Carpenter, S., Ahuja, S., Goldenberg, N., Woods, G., Godder, K., Scott-Emuakpor, A., Roach, G., Raffini, L., Shah, N., Shah, S., Thornburg, C., Zia, A., Berkow, R., Male, C., Lensing, A. W. A., Palumbo, J. S., Kumar, R., Nurmeev, I., Hege, K., Bonnet, D., Connor, P., Hooimeijer, H. L., Torres, M., Chan, A. K. C., Kenet, G., Holzhauer, S., Santamaría, A., Amedro, P., Chalmers, E., Simioni, P., Bhat, R. V., Yee, D. L., Lvova, O., Beyer-Westendorf, J., Biss, T. T., Martinelli, I., Saracco, P., Peters, M., Kállay, K., Gauger, C. A., Massicotte, M. P., Young, G., Pap, A. F., Majumder, M., Smith, W. T., Heubach, J. F., Berkowitz, S. D., Thelen, K., Kubitza, D., Crowther, M., Prins, M. H., Monagle, P., Molinari, A. C., Nowak, Göttl, U., Chain, J., Robertson, J., Thom, K., Streif, W., Schwarz, R., Schmitt, K., Grangl, G., Van Damme, A., Maes, P., Labarque, V., Petrilli, A., Loggeto, S., Azeka, E., Brandao, L., Le, D., Sabapathy, C., Giordano, P., Wu, R., Ding, J., Huang, W., Mao, J., Lähteenmäki, P., Decramer, S., Bernig, T., Chada, M., Chan, G., Kally, K., Nolan, B., Revel-Vilk, S., Tamary, H., Levin, C., Tormene, D., Abbattista, M., Artoni, A., Ikeyama, T., Inuzuka, R., Yasukochi, S., Morales Soto, M., Solis Labastida, K. A., Suijker, M. H., Bartels, M., Tamminga, R. Y., Van Ommen, C. H., Te Loo, D. M., Anjos, R., Zubarovskaya, L., Popova, N., Samochatova, E., Belogurova, M., Svirin, P., Shutova, T., Lebedev, V., Barbarash, O., Koh, P. L., Mei, J. C., Podracka, L., Berrueco, R., Fernandez, M. F., Frisk, T., Grunt, S., Rischewski, J., Albisetti-Pedroni, M., Antmen, A., Tokgoz, H., Karakas, Z., Motwani, J., Williams, M., Grainger, J., Payne, J., Richards, M., Baird, S., Bhatnagar, N., Aramburo, A., Crary, S., Wynn, T., Carpenter, S., Ahuja, S., Goldenberg, N., Woods, G., Godder, K., Scott-Emuakpor, A., Roach, G., Raffini, L., Shah, N., Shah, S., Thornburg, C., Zia, A., and Berkow, R.
- Abstract
Background: Treatment of venous thromboembolism in children is based on data obtained in adults with little direct documentation of its efficacy and safety in children. The aim of our study was to compare the efficacy and safety of rivaroxaban versus standard anticoagulants in children with venous thromboembolism. Methods: In a multicentre, parallel-group, open-label, randomised study, children (aged 0–17 years) attending 107 paediatric hospitals in 28 countries with documented acute venous thromboembolism who had started heparinisation were assigned (2:1) to bodyweight-adjusted rivaroxaban (tablets or suspension) in a 20-mg equivalent dose or standard anticoagulants (heparin or switched to vitamin K antagonist). Randomisation was stratified by age and venous thromboembolism site. The main treatment period was 3 months (1 month in children <2 years of age with catheter-related venous thromboembolism). The primary efficacy outcome, symptomatic recurrent venous thromboembolism (assessed by intention-to-treat), and the principal safety outcome, major or clinically relevant non-major bleeding (assessed in participants who received ≥1 dose), were centrally assessed by investigators who were unaware of treatment assignment. Repeat imaging was obtained at the end of the main treatment period and compared with baseline imaging tests. This trial is registered with ClinicalTrials.gov, number NCT02234843 and has been completed. Findings: From Nov 14, 2014, to Sept 28, 2018, 500 (96%) of the 520 children screened for eligibility were enrolled. After a median follow-up of 91 days (IQR 87–95) in children who had a study treatment period of 3 months (n=463) and 31 days (IQR 29–35) in children who had a study treatment period of 1 month (n=37), symptomatic recurrent venous thromboembolism occurred in four (1%) of 335 children receiving rivaroxaban and five (3%) of 165 receiving standard anticoagulants (hazard ratio [HR] 0·40, 95% CI 0·11–1·41). Repeat imaging showed an improved eff
- Published
- 2020